Growth intact, but execution masks show
Reported PAT growth of 28.5% includes ₹7 crore in one-time gains; organic profit is closer to 15%, while flat QoQ and deliberate ticket compression for affordability raise execution questions despite solid multi-year fundamentals.
₹65.9 Cr
+28.5% YoY
₹7 Cr
warrant ₹5 Cr, capital gains ₹2.5 Cr
~₹60 Cr
sustainable organic run-rate
Jeena Sikho's headline PAT of ₹65.9 crore lands within guidance — but the quarter's real story sits underneath. Revenue of ₹224.4 crore is a credible 28.8% YoY and matches the company's stated 30% growth target. The problem: volume gains (IPD +33%, OPD +22%) are not flowing through to revenue proportionally, and management's response — deliberately cutting ticket sizes for Ayushman Yojana prep and exiting its government Panchakarma business — exposes near-term margin compression and raises the question of whether organic growth is truly in the high 20s or closer to mid-teens.
Where the reported profit came from
Other income jumped to ₹14 crore this quarter from ₹4 crore last quarter. Of that ₹14 crore, ₹7 crore is one-time: warrant revaluation (₹5 crore) and capital gains (₹2.5 crore). On the call, CFO Nanak Chand acknowledged this and pencilled in a recurring base of ₹4–5 crore. Strip out the one-time items, and normalized PAT lands at roughly ₹60 crore — closer to a 15% organic gain year-on-year, not 28.5%. The reported figure is a function of financial-year flatness recovering with an earnings boost, not operational acceleration.
The volume-revenue gap — where strategy masks execution
IPD admissions jumped 33% year-on-year to 11,500 patients. OPD volume grew 22%. Yet Panchakarma service revenue — the core — grew only 13%. Management's explanation: two deliberate moves.
First, ticket-size compression for affordability: In preparation for the Ayushman Yojana government rollout (expected within 2–6 months), management is pre-filling discounted beds at ₹4,000–₹6,000 per patient, down from prior ₹8,000–₹10,000 for private Panchakarma. CFO Nanak Chand disclosed plans to fill 500 discounted beds within 10 days. The trade-off: occupancy will rise (currently 59% on 2,400 beds), but average revenue per patient will fall until Ayushman reimbursements and premium patient mix improve. On the call, management asserted this compression will recover, but no timeline was given.
Second, government business exit: Government-sponsored Panchakarma revenue fell from ₹15 crore (Q1 FY26) to ₹5 crore (Q1 FY27) — a ₹10 crore headwind. Management's rationale: receivables risk and credit friction. The company is betting that private business growth (~30% organically) and products (+47% YoY) will more than offset. Private business is delivering, but the strategy is a trade-off, not a tailwind. It shows in QoQ flatness: revenue edged up just 4.1% quarter-on-quarter despite adding 100 beds.
What changed on this call
Revenue grew 29% YoY, EBITDA margin 41%, PAT margin 28%
Delivered: ₹224.4 Cr revenue, 28.8% YoY, 41% OPM, 27.6% NPM — all on target.
Supported
IPD volume up 33%, OPD up 22%, Panchakarma revenue up 13%
Volume gains real; revenue soft because of ticket size cuts (₹4–6k beds for Ayushman prep) and ₹10 Cr government exit.
Overstated on conversion
Product business grew 47% YoY, medicine sales stable at ₹118 Cr
No independent audit; consistent with e-commerce customer growth (228k → 264k). Plausible.
Supported
Bed occupancy 59% on 2,400 beds, added 100 beds this quarter
Stated; path to 3,000–3,500 beds in FY27 (9 months remaining) not detailed. Capex plan sparse.
Partially stated
PAT 65.9 Cr reflects strong operational leverage
Other income ₹14 Cr includes ₹7 Cr one-time (warrant ₹5 Cr, capital gains ₹2.5 Cr); normalized PAT ~₹60 Cr.
Overstated; quality concern
Three new strategic moves emerged on this call.
Manali premium wellness (Sep–Oct 2026): 108 rooms + villas targeting ₹32–37k ADR, 35–40% EBITDA margins. A lease deal with minimal opex (wage + marketing only), positioned to deliver ₹3–5 crore net profit from FY28 onwards. This is a hedge: as mid-market Ayushman beds compress margins, ultra-luxury insulates OPM.
Entero OTC distribution: Partnership goes live within 2 weeks of the call (Aug 07), scaling Pet Shuddhi and OTC products beyond direct e-commerce (264k customers) and clinic channels. Incremental revenue not guaranteed but widens product TAM.
Colors TV brand integration (6-month deal): ₹4 crore ad spend booked to Q1 (front-loaded), but benefits (Anupamaa, Khatron Ke Khiladi, Laughter Chefs integration) expected Q2 onwards. This is multi-quarter capex for brand awareness.
YoY growth (28.8% revenue, 28.5% PAT) aligns with 30% target
EBITDA margin discipline: 41% holds above 40% guidance
Multi-year roadmap (7k–10k beds, ₹3,000 Cr revenue, ₹1,000 Cr PAT) reaffirmed
Luxury wellness (Manali, 35–40% EBITDA) is a new margin buffer
IPD volume +33%, OPD +22% show strong patient pull-through
Reported PAT inflated ~10% by one-time gains (warrant ₹5 Cr, gains ₹2.5 Cr)
QoQ revenue flat (4.1%) despite bed additions; near-term momentum soft
Ticket size compression for Ayushman may not recover; ARPU elasticity unproven
Government business cut ₹10 Cr intentionally; masks underlying organic growth
Capex for 600+ beds in FY27 (reach 3k beds) has no detailed funding roadmap
Ayushman Yojana launch timing (2–6 months) uncertain; government schedules fluid
How the street is positioned
The market's reaction was swift and harsh. On day 1 post-result, the stock fell 9.72%; by day 3, it was down 14.48% from the pre-result close of ₹598.1. Current price of ₹521.35 is 12.8% below the result announcement level and down 37.56% from its all-time high of ₹835. The stock trades below all key moving averages (SMA20 ₹562.6, SMA50 ₹576.57, SMA200 ₹653.38); RSI of 38 is neutral, neither momentum nor extreme oversold.
Institutional flows are turning negative: FII ownership fell from 6.17% (Q4 FY26) to 4.78% (Q1 FY27), a 1.39 percentage-point trim. DII ownership is negligible (0.36%, flat). Promoter holding is steady at 63.62%, indicating no insider selling signal. Bulk/block trades in the ₹688–₹695 range over 6 months show no major promoter or insider-linked selling near highs; activity appears to be proprietary volume.
This positioning makes sense: the sell-off reflects genuine concerns about earnings quality (one-time gains), QoQ momentum (flat), and execution risk (capex, Ayushman timing). FII selling is consistent with risk-off stance on high-growth, capital-intensive healthcare. However, at 37.56% below ATH and below all long-term averages, the stock has priced in the bear case. If Ayushman fills beds on schedule and luxury wellness ramps EBITDA, the multiple could re-rate upwards.
Ayushman Yojana launch delays
HighManagement is banking on 500+ discounted beds to fill early Q2. Scheme is PMO-approved but state-level payment rates are still being finalized (wide 2–6 month window). Payment cycles post-discharge are 3–4 months, adding cash-flow friction. Delay = occupancy ramp and margin recovery stall.
Earnings quality: one-time gains masking organic slowdown
HighReported PAT ₹65.9 Cr; adjusted PAT ~₹60 Cr (15% organic growth). If warrant valuation is temporary or capital gains don't recur, Q2 PAT could compress 10–15% YoY. Street is already pricing this risk (steep sell-off).
Capex execution for 3,000–3,500 beds in FY27
MediumCurrently 2,400 beds (+100 Q1). Panvel (49 beds, OC/fire approval pending); Manali (108 rooms, Sep–Oct launch). Need 600+ beds in 9 months. No detailed funding roadmap or approval timeline disclosed. If capex slips or funding tightens, bed count target will miss.
Ticket size compression margin recovery uncertainty
MediumPanchakarma revenue +13% YoY despite IPD volume +33%. Ticket sizes cut from ₹8–10k to ₹4–6k for affordability. If premium patient flow slows or Ayushman reimbursement rates are lower than expected, ARPU recovery timeline may extend.
Entero OTC distribution channel execution
MediumPartnership launches within 2 weeks (by mid-Aug 2026). Incremental revenue not guaranteed; sell-through depends on distributor effectiveness. Failed channel partnership would weigh on product growth guidance.
Competitive pressure in OTC Ayurveda segment
LowPet Shuddhi priced at ₹800+ premium vs. competitor Pet Saffa. Management claims 4x manufacturing cost due to root-cause formulation. Pricing premium is unproven at scale; competitor discounting could force margin pressure.
1 · Entero OTC distribution ramp
Within 2 weeks of the call (mid-Aug 2026), the partnership goes live. Track channel velocity (orders shipped, customer count, retail shelf presence) in Aug–Sep. This is a bellwether for product segment momentum.
2 · Manali premium wellness launch (Sep–Oct 2026)
Opening of the ultra-luxury center will test the ₹32–37k ADR and 35–40% EBITDA margin thesis. First full quarter of data comes in Q3 FY27; watch for actual occupancy, ARPU, and cost discipline.
3 · Ayushman Yojana rollout timing (2–6 months from Aug 07)
Government scheme is the lynchpin for occupancy and margin recovery post-ticket compression. Watch for state-level rate finalization, payment infrastructure go-live, and the company's bed-filling ramp (management promised 500 discounted beds within 10 days; track actual fill rates and payment cycles).
4 · Q2 FY27 organic run-rate (by late Oct / early Nov 2026)
Strip out one-time gains. Watch for Q2 other income falling back to ₹4–5 Cr recurring base, which will show true organic PAT without MTM or capital gains. If organic PAT flattens despite Ayushman pre-fill, execution risk rises significantly.
5 · Bed expansion progress (600+ beds to reach 3k–3.5k in FY27)
Panvel and Manali are the near-term sources. Track regulatory approvals (OC, fire, pollution clearance), capacity ramp, and occupancy by segment. If progress stalls, the FY27 bed target will likely miss.
Jeena Sikho is executing a solid multi-year plan: ₹3,000 crore revenue and ₹1,000 crore PAT within 3–5 years is credible given 7,000–10,000 beds and luxury wellness expansion. But this quarter is a reminder that the path is not linear. Reported growth of 28.5% masks organic growth closer to 15%; QoQ flatness signals transition costs; deliberate ticket compression is a trade-off, not a free carry.
The single number to track from here is organic PAT (adjusted for one-time items). If Q2 FY27 organic PAT grows at 15% or better YoY and Ayushman bed-fill progresses as guided, the growth thesis holds and the stock's 37% drawdown offers opportunity. If organic PAT flattens, Ayushman delays, or capex slips, the multiple re-rates downward. At current levels, the stock has priced in the bear case; the next two quarters will determine whether management executes or manages expectations downward.
Jeena Sikho Q1 FY27: PAT +29% YoY on consolidated basis, but core margin slips 416bps
PAT +28.51% YoY · revenue +28.76% · margins compressing · miss vs street
₹224.4 Cr
+28.76% YoY
₹65.89 Cr
+28.51% YoY
27.6%
-1.6pp YoY
₹5.3
Jeena Sikho Lifecare's consolidated Q1 FY27 (quarter ended June 30, 2026) print shows revenue of ₹224.40 Cr, up 28.8% YoY (from ₹174.29 Cr) and 4.1% QoQ, with PAT of ₹65.89 Cr, up 28.5% YoY (from ₹51.27 Cr) and 46.2% QoQ. Because revenue and profit grew almost in lockstep YoY, net margin held essentially flat at 29.36% versus 29.24% a year ago — but that headline masks a real deterioration underneath: operating margin (PBT + finance cost + depreciation − other income, over revenue) compressed to 41.03% from 45.19% a year ago, a 416bps YoY squeeze, even as it improved sharply from 36.15% in the seasonally softer Q4 FY26. The gap between the two margins was bridged almost entirely by other income, which jumped roughly 13x YoY to ₹14.33 Cr from ₹1.07 Cr — without that swing, PAT growth would have been closer to high-single-digits YoY rather than the 28.5% reported. Both revenue and PAT came in below the (non-formal, trailing-growth) Q1 FY27 estimates published by Univest — revenue ₹245-281 Cr, PAT ₹68-86 Cr — though this isn't a formal institutional consensus and should be read cautiously.
Q1 FY-2027 vs prior quarters
The operating-margin squeeze traces to costs running well ahead of revenue: employee benefits expense rose 53.5% YoY (₹45.99 Cr vs ₹29.96 Cr), depreciation 59.4% YoY (₹15.39 Cr vs ₹9.65 Cr), and finance costs more than doubled (₹3.47 Cr vs ₹1.66 Cr) — consistent with the capacity build-out (clinics, staff, wellness infrastructure) management flagged on the Q4 FY26 call, ahead of the revenue those assets are meant to generate. At the segment level, Ayurvedic products/medicines revenue grew 47.8% YoY to ₹118.28 Cr while Ayurvedic healthcare services grew a slower 11.1% YoY to ₹104.75 Cr; products drove this quarter's topline beat, aided by new launches (Amrit Dhara Drops, pain-relief patches) and a wellness-centre agreement signed August 6. Segment margins compressed at both businesses YoY — products to 34.9% from 37.6%, services to 40.8% from 45.5% — mirroring the group-level trend.
The stock went into the print at ₹598.1, up 1.1% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 5 quarters; revenue is at a 5-quarter high.
What the summary numbers don't show
Consolidated basic EPS ₹5.30, up from ₹4.12 a year ago and ₹3.63 in Q4 FY26
Management is highly optimistic about future growth, projecting a 4x to 5x increase in PAT within 3-5 years, with a target revenue of INR 3,000 crores. They anticipate a 50-50 split between the services and products businesses. The company plans to significantly expand its bed capacity, aiming for 7,000 to 10,000 beds
Management's Q4 FY26 guidance was long-horizon (4-5x PAT and ₹3,000 Cr revenue over 3-5 years, 7,000-10,000 beds over the same window, with a near-term target of 2,800-3,000 operational beds within 3-4 months of the June 2, 2026 call, i.e. by roughly September-October 2026) and isn't directly testable off one quarter's numbers; that near-term bed milestone hasn't come due yet, so vsGuidance is unknown rather than met or missed. The Board also approved selling the Derabassi hospital's land and building for ₹9.05 Cr (6-8% of standalone revenue), expected to close in Q2 FY27, with operations continuing on a leaseback — a balance-sheet move, not a revenue hit. Separately, the UAE subsidiary's planned 51% stake in Back to Roots Ayurveda (BTRS) remains stuck on regulatory registration, with only a ₹0.53 Cr profit share booked this quarter — international expansion is still pre-scale. No management press release/commentary was available in our records for this print, so the read here rests on the filing and segment note alone.
W1
Bed-capacity ramp: management's target of 2,800-3,000 operational beds within 3-4 months of the June 2, 2026 call (~Sept-Oct 2026) — not yet visible in Q1 numbers
W2
Other income sustainability: ₹14.33 Cr this quarter vs ₹1.07 Cr a year ago cushioned NPM; a normalization would pull NPM back toward the 41% operating-margin trend
W3
Derabassi hospital sale (₹9.05 Cr) expected to close in Q2 FY27 — watch treatment of the gain and post-sale lease terms
Figures converted from Rs. lacs (÷100). Consolidated PAT taken as 'Profit for the quarter' (₹65.89 Cr, incl. NCI loss of ₹0.06 Cr) to match our historical comparison convention; owners-attributable PAT (used for EPS) is slightly higher at ₹65.95 Cr. No exceptional/one-off items in either the current or year-ago quarter, so no adjusted-YoY figure is needed. Q4 FY26 comparative column is a derived balancing figure (note 5, not separately reviewed); Q1 FY26 comparatives were audited by predecessor auditor KRA & Co.
Growth on track, but one-time gains mask QoQ flatness
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Hit YoY growth targets (30% guided, 28.8% delivered). Q1 execution shows strategic trade-offs (ticket compression, government exit) to build future. Bed expansion on track; prior multi-quarter targets met on revenue, margins. One-time gains used to prop PAT; quality concern.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
YoY growth aligns with 30% target (28.8% revenue, 28.5% PAT), supporting multi-year ₹3,000 Cr ambition. However, ₹7 Cr in one-time income inflates PAT by ~8%; QoQ revenue nearly flat despite bed capacity and volume gains; management deliberately cutting ticket size and government business to build occupancy and cash model. Near-term execution risks (Ayushman timing, capex, occupancy ramp) warrant cautious stance despite solid directional progress.
₹224.4 Cr
Revenue · +28.8% YoY₹65.9 Cr
Reported PAT · +28.5% YoYFlat
Margins · vs guidance: CorroboratedDid the claims hold up?
Revenue grew 29% YoY, EBITDA margin 41%, PAT margin 28%
METDelivered: 224.4 Cr revenue, 28.8% YoY growth, 41% OPM, 27.6% NPM
IPD volume up 33%, OPD up 22%, Panchakarma revenue up 13%
OVERSTATEDVolume gains not translating to proportional revenue; ticket size reduced for Ayushman prep, government business cut from 15 to 5 Cr
Product business grew 47% YoY, medicine sales stable at 118 Cr
METNo independent audit shown, but consistent with ecosystem narrative; e-commerce customers grew from 228k to 264k
Bed occupancy 59% on 2,400 beds, added 100 beds this quarter
OVERSTATEDStated but growth path to 3,000 beds in FY27 not detailed; capex plan unclear
PAT 65.9 Cr reflects strong operational leverage
OVERSTATEDOther income jumped to 14 Cr with 7 Cr one-time items (warrant valuation 5 Cr, capital gains 2.5 Cr); normalized PAT ~57-61 Cr
Earnings quality
What changed since the last call
Deliberate ticket size compression
DowngradeManagement now actively lowering per-patient revenue in affordability segment (₹4-6k beds for Ayushman prep) vs prior push for premium pricing. Trade: occupancy vs ARPU. Prior guidance held premium as 50-50 mix.
Government business contraction
DowngradeGovernment Panchakarma ₹15 Cr (Q1 FY26) → ₹5 Cr (Q1 FY27). Strategic but ₹10 Cr headwind masked by product growth +47% and price discipline elsewhere.
New ultra-luxury segment
NewManali premium wellness center (108 rooms, 22 villas) targeting ₹32-37k ADR, 35-40% EBITDA margin. Strategic deal: minimal opex (wage/marketing only), high-margin play. Prior calls did not detail luxury segment.
Entero partnership formalized
NewOTC product distribution through Entero (testing complete, live within 2 weeks). Adds retail channel to e-commerce and direct sales. Prior guidance mentioned product expansion; now concrete vendor.
Bed expansion timeline firm
Maintained3,000-3,500 beds FY27 (currently 2,400, +100 Q1). 7,000-10,000 in 3-5 years. Same as prior calls; no acceleration or deceleration stated.
The Q&A
Analysts pressed hard on volume-revenue disconnect (IPD +33%, revenue +13%); management initially deflected (don't judge QoQ), then disclosed ticket size cuts and government exit. Q&A credible but defensive tone on near-term softness. No analyst challenged PAT quality or one-time gains heavily.
QoQ revenue flatness — Karanveer Singh, Nuvama Health
PartialDon't judge QoQ; quarterly fluctuation normal. Business model shift underway: reducing low-margin government business, investing in brand, expanding daycare. Per-day daycare volume up 16k→19k; overall occupancy up 10% YoY.
Volume-revenue gap — Aditya Chheda, InCred Asset Management
PartialComplex: daycare now 31% YoY growth (separate line); OPD/COD/consulting +143% YoY (lead indicators). Incremental OPD still converting to Panchakarma; natural lag. Margins hold 41% EBITDA because of mix shift.
Ticket size reconciliation — Sunil, VK Investments
AnsweredYes, deliberately. Reduced ticket size for poor/BPL patients to prep for Ayushman Yojana (₹4-6k beds). Government business down ₹10 Cr. When Ayushman launches, will be ready operationally; occupancy will drive margin recovery.
Other income spike — Rusmik, 9 Rays EquiResearch
Answered₹7 Cr one-time (warrant revaluation ₹5 Cr, capital gains ₹2.5 Cr). Recurring base ₹4-5 Cr from mutual funds, FDs. No structural change.
One-off expenses — Deepak Poddar, Sapphire Capital
AnsweredAd expense +₹4 Cr (6-month Colors TV deal; benefits Q2+), software ₹2 Cr, audit ₹0.5 Cr. Will continue as brand-building; not one-time in magnitude.
Product business growth — Naveen Baid, Nuvama AMC
AnsweredOur product 4x manufacturing cost of competitors; includes four-shot formulation targeting root cause (Mand Agni, liver, spleen, metabolism) vs stomach-only cleanse. Different positioning, not just repackaging.
Manali premium wellness model — Rusmik, 9 Rays
AnsweredFY27: minimal (launches Sep-Oct, cold season Nov-Feb). FY28: 35-room guarantee, 50% occupancy, ₹32-35k ADR, 35-40% EBITDA. Year two: 60% occupancy, 35-37k ADR, 60% gross margin, 9-10% opex only. Strategic deal (no cost for utilities, only wage/marketing).
Bed expansion plan — Deepak Poddar, Sapphire Capital
PartialPanvel: 49 beds now (OC/fire approval ongoing). Meerut standalone ₹15 Cr revenue on out-of-city model. As Panvel scales to 250 beds, revenue will 4-5x. Manali launch full post-approvals. Process is slow but planned.
Guidance outlook — Aditya Chheda, InCred
AnsweredWill maintain 27-30% NPM and 40%+ EBITDA margin in future. Focus on occupancy + premium wellness to drive leverage. No margin compression expected.
Guidance
INR 3,000 crore by FY29-30 (3 years max, ideally before 5 years)
MediumReaffirmed from prior calls. At 30% CAGR from ~₹900 Cr annualized base: ₹900 × (1.3)² = ₹1,521 Cr in 2 years, ₹1,976 Cr in 3 years. Path requires 7,000-10,000 beds + luxury wellness expansion on track.
Maintain 27-30% NPM and 40%+ EBITDA margin
MediumQ1 delivered 27.6% NPM (core ~25-26% ex-one-time gains), 41% EBITDA. Ticket size compression may pressure near-term, but premium wellness (35-40% EBITDA target) offsets. No formal FY27 target stated.
3,000-3,500 beds in FY27; 7,000-10,000 beds in 3-5 years
LowCurrently 2,400 operational (+100 Q1). Panvel (49 beds, approval pending), Manali (108 rooms). Capex required but not quantified. Execution risk on approvals and occupancy ramp.
Risks the call surfaced
Regulatory & Government
HighManagement banking on Ayushman for 500+ discounted bed occupancy. Scheme approved by PMO but ministry-level rates still being set (4 days ago). 2-6 month window uncertain. Payment cycles historically 3-4 months post-discharge.
Execution & Capex
MediumCurrently 2,400 beds, +100 Q1. Target 600+ beds in 9 months. Panvel stuck at 49 beds (OC/fire approval pending); Manali launching Sep-Oct but limited capacity (108 rooms + villas). No detailed capex roadmap or funding plan disclosed.
Pricing & Margin
MediumManagement deliberately lowering per-patient revenue in discounted segment (₹4-6k Ayushman beds vs. ₹8-10k prior private). Boosts occupancy but compresses ARPU. If premium patient flow slows, margin recovery may lag.
Earnings Quality
Medium₹14 Cr other income includes ₹7 Cr one-time (warrant revaluation ₹5 Cr, capital gains ₹2.5 Cr). Reported PAT 65.9 Cr; normalized ~57-61 Cr. If warrant expires or investment gains don't recur, PAT will compress 8-10%.
Competition & Positioning
LowManagement claims Pet Shuddhi 4x manufacturing cost of Pet Saffa competitor due to root-cause formulation. Price gap ₹800+ maintained. If consumer education fails, premium positioning may not sustain; competitor discounting could force margin pressure.
Management
Score 7/10. Clear long-term vision (prevention-first ecosystem, healthspan focus) and strategic philosophy well-articulated. However, defensive on QoQ metrics; initially evasive on volume-revenue gap (took analyst pressing to disclose ticket size cuts). Transparent on one-time gains and expenses after questioned. Met YoY guidance (28.8% growth vs. 30% target). Bed expansion on track (2,400 beds, multi-year plan visible). Prior calls' targets (3,000 Cr revenue, 1,000 Cr PAT, 30% growth) reaffirmed without update; no acceleration shown. One-time gains used to prop PAT; quality concern.
1 · Next 15 days
Entero OTC product distribution launch across 2-week ramp
2 · Sep-Oct 2026
Manali premium wellness (Jeena Sikho Premium) opens; 35-room minimum guarantee
3 · 2-6 months
Ayushman Yojana government rollout; management pre-filling discounted beds
Near-term execution risks (Ayushman timing, capex, occupancy ramp) warrant cautious stance despite solid directional progress.